Owing to the growing number of approvals of cell therapies, and a continuous rise in number of associated clinical trials, the demand for advanced cell therapy consumables is likely to witness
/PRNewswire/ Roots Analysis has announced the addition of Cell Therapy Media Market, Cell Therapy Kits market, Cell Therapy Reagents Market and Cell Therapy.
Hemostemix Announces Closing of $2,750,000 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Calgary, Alberta (Newsfile Corp. - March 23, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce that it has entered into a settlement
(Getty/FamVeld)
As it awaits FDA feedback on its pivotal trial for its leading med, Minovia Therapeutics has hired Alan Jacobs, M.D., Ph.D., to help boost it over the line.
The U.S.-Israel biotech, which uses a platform to augment disease caused by mitochondrial dysfunction, will now tap Jacobs’ 20 years’ experience at companies including Aspire Health Science, Hemostemix and PerceptiMed.
As CMO, he will now lead Minovia’s clinical operations and regulatory affairs, including speeding up the development plans for Pearson Syndrome and other “primary and secondary mitochondrial diseases,” the biotech said in a statement.
Currently, Minovia is working on an IND-enabled phase 1/2 test in Pearson syndrome, a fatal pediatric disease. It hopes that by harnessing the power of mitochondria, membrane-bound cell organelles that generate most of the chemical energy needed to power the cell s biochemical reactions, it can help address this unmet medical need and hit other